Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.

Alimera Sciences’ advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide, a corticostercoid which may be useful in the treatment of ocular disease. ILUVIEN is under review at the US FDA and 7 European health authorities for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Alimera Sciences’ management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and are dedicated and focused to making Alimera a leading ophthalmic biopharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialization of ophthalmic products. Our strategy behind Alimera is to:

• Bring to market ILUVIEN ^® , now under review by the FDA, for the treatment of DME.
• Continue evaluating ILUVIEN for other ophthalmic indications.
• Evaluate the use of NADPH Oxidase inhibitors for ophthalmic diseases
• Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
• Operate as an ethically driven company, recognizing our responsibility to others and the importance of having a positive impact on those with whom we interact.

Areas of Focus

Alimera Sciences specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina.

Our team is committed to the development of therapies for eye conditions that will affect millions of people in our aging population, many of which lead to irreversible damage when left untreated. Research indicates that as many as 12,000-24,000 new cases of blindness reported annually are caused by complications from diabetes alone.

To date, Alimera’s research has focused primarily on the following conditions:

• Diabetic retinopathy
• Diabetic macular edema (DME)
• Retinal vein occlusion (RVO)
• Age-related macular degeneration (AMD)

Products Overview

At Alimera Sciences, we are dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our development portfolio, studying compounds to treat early- and late-stage diseases such as diabetic macular edema, wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Today, our primary focus is on ILUVIEN^®, a tiny, cylindrical polyimide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid with a history of treating ocular diseases.

In addition to activities related to the development of ILUVIEN, we have acquired options to exclusive, worldwide licenses of patent applications covering NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors from Emory University.